Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1068-1074

  Ruslami, Rovina ^a   Nijland, Hanneke M J ^b   Adhiarta, I Gusti N ^a   Kariadi, Sri H K S ^a   Alisjahbana, Bachti ^a   Aarnoutse, Rob E ^b   Van Crevel, Reinout ^b  

^a PADJADJARAN UNIVERSITY   (Indonesia)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DESACETYLRIFAMPIN; ETHAMBUTOL; GLUCOSE; HUMAN INSULIN; INSULIN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAMPICIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETIC PATIENT; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INDONESIA; LIVER; LUNG TUBERCULOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION; PRIORITY JOURNAL; SAMPLING; STEADY STATE; TREATMENT FAILURE;

ADULT; ANTITUBERCULAR AGENTS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; ETHAMBUTOL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 77149159420     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00447-09     Document Type: Article

References (32)

1. Alisjahbana, B., R. van Crevel, E. Sahiratmadja, M. Heijer, A. Maya, E. Istriana, H. Danusantoso, T. H. Ottenhoff, R. H. Nelwan, and J. W. van der Meer. 2006. Diabetes mellitus is strongly associated with tuberculosis in Indonesia. Int. J. Tuberc. Lung Dis. 10:696-699.
2. Alisjahbana, B., E. Sahiratmadja, E. J. Nelwan, A. M. Purwa, Y. Ahmad, T. H. Ottenhoff, R. H. Nelwan, I. Parwati, J. W. van der Meer, and R. van Crevel. 2007. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin. Infect. Dis. 45:428-435.
3. Boucot, K. R. 1957. Diabetes mellitus and pulmonary tuberculosis. J. Chronic Dis. 6:256-279.
4. Burman, W. J., K. Gallicano, and C. A. Peloquin. 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40:327-341.
5. Fromm, M. F., D. Busse, H. K. Kroemer, and M. Eichelbaum. 1996. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796-801.
6. Gadkowski, L. B., and J. E. Stout. 2007. Pharmacokinetics of rifampicin. Clin. Infect. Dis. 44:618-619. (Letter to the editor.)
7. Guptan, A., and A. Shah. 2000. Tuberculosis and diabetes: an appraisal. Indian J. Tuberc. 47:3-8.
8. Houin, G., A. Beucler, S. Richelet, R. Brioude, C. Lafaix, and J. P. Tillement. 1983. Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculous patients after different rates of infusion. Ther. Drug Monit. 5:67-72.
9. Immanuel, C., P. Gurumurthy, G. Ramachandran, P. Venkatesan, V. Chandrasekaran, and R. Prabhakar. 2003. Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or combination of three drugs. Indian J. Med. Res. 118:109-114.
10. Jain, A., V. L. Mehta, and S. Kulshrestha. 1993. Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis. Tuber. Lung Dis. 74:87-90.
11. Kimerling, M. E., P. Phillips, P. Patterson, M. Hall, C. A. Robinson, and N. E. Dunlap. 1998. Low serum antimycobacterial drug levels in non-HIVinfected tuberculosis patients. Chest 113:1178-1183.
12. Nejentsev, S., T. Thye, J. S. Szeszko, H. Stevens, Y. Balabanova, A. M. Chinbuah, M. Hibberd, E. van de Vosse, B. Alisjahbana, R. van Crevel, T. H. Ottenhoff, E. Png, F. Drobniewski, J. A. Todd, M. Seielstad, and R. D. Horstmann. 2008. Analysis of association of the TIRAP (MAL) S180L variant and tuberculosis in three populations. Nat. Genet. 40:261-262.
13. Niemi, M., J. T. Backman, M. F. Fromm, P. J. Neuvomen, and K. T. Kivisto. 2003. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42:819-850.
14. Nijland, H. M. J., R. Ruslami, J. E. Stalenhoef, E. J. Nelwan, B. Alisjahbana, R. H. Nelwan, A. van der Ven, H. Danusantoso, R. E. Aarnoutse, and R. van Crevel. 2006. Exposure to rifampicin is strongly reduced in tuberculosis patients with type 2 diabetes. Clin. Infect. Dis. 43:848-854.
15. Nijland, H. M. J., R. E. Aarnoutse, R. Ruslami, and R. van Crevel. 2007. Reply to Gadkowski and Stout. Clin. Infect. Dis. 44:619.
16. Nijland, H. M. J., R. Ruslami, A. J. Suroto, D. M. Burger, B. Alisjahbana, R. van Crevel, and R. E. Aarnoutse. 2007. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin. Infect. Dis. 45: 1001-1007.
17. Pargal, A., and S. Rani. 2001. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. Int. J. Tuberc. Lung Dis. 5:70-79.
18. Peloquin, C. A. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183.
19. Restrepo, B. I. 2007. Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances. Clin. Infect. Dis. 45:436-438.
20. Ruslami, R., H. Nijland, R. Aarnoutse, B. Alisjahbana, A. Y. Soeroto, S. Ewalds, and R. van Crevel. 2006. Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis. Antimicrob. Agents Chemother. 50:822-823.
21. Ruslami, R., H. J. Nijland, B. Alisjahbana, I. Parwati, R. van Crevel, and R. E. Aarnoutse. 2007. Pharmacokinetics and tolerability of a higher rifampicin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 51:2546-2551.
22. Ruslami, R., R. van Crevel, E. van de Berge, B. Alisjahbana, and R. E. Aarnoutse. 2008. A step-wise approach to find a valid and feasible method to detect non-adherence to tuberculosis drugs. Southeast Asian J. Trop. Med. Public Health 39:1083-1087.
23. Sahai, J., K. Gallicano, L. Swick, S. Tailor, G. Garber, I. Seguin, L. Oliveras, S. Walker, A. Rachlis, and D. W. Cameron. 1997. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann. Intern. Med. 127:289-293.
24. Singla, R., N. Khan, N. Al-Sharif, M. O. Al-Sayegh, M. A. Shaikh, and M. M. Osman. 2006. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int. J. Tuberc. Lung Dis. 10:74-79.
25. Stevenson, C. R., N. G. Forouhi, G. Roglic, B. G. Williams, J. A. Lauer, C. Dye, and N. Unwin. 2007. Diabetes and tuberculosis: the impact of diabetes epidemic on tuberculosis incidence. BMC Public Health 7:234.
26. van Crevel, R., R. H. Nelwan, F. Borst, E. Sahiratmadja, J. Cox, W. van der Meij, M. de Graaff, B. Alisjahbana, W. C. de Lange, and D. Burger. 2004. Bioavailability of rifampicin in Indonesian subjects: a comparison of different local drug manufacturers. Int. J. Tuberc. Lung Dis. 8:500-503.
27. Venkatesan, K. 1992. Pharmacokinetic drug interactions with rifampicin. Clin. Pharmacokinet. 22:47-65.
28. Wild, S., G. Roglic, A. Green, R. Sicree, and H. King. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053.
29. Wilkins, J. J., G. Langdon, H. McIlleronn, G. C. Pillai, P. J. Smith, and U. S. H. Simonsson. 2006. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur. J. Clin. Pharmacol. 62:727-735.
30. Wilkins, J. J., R. M. Savic, M. O. Karlson, G. Langdon, H. McIlleron, G. Pillai, P. J. Smith, and U. S. H. Simonsson. 2008. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52:2138-2148.
31. World Health Organization. 1999. Definition, diagnosis and classification of diabetes mellitus and its complications. World Health Organization, Geneva, Switzerland.
32. Zhu, M., W. J. Burman, J. R. Starke, J. J. Stambaugh, P. Steiner, A. E. Bulpitt, D. Ashkin, B. Auclair, S. E. Berning, R. W. Jelliffe, G. S. Jaresko, and C. A. Peloquin. 2004. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int. J. Tuberc. Lung Dis. 8:1360-1367.